TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, a few mutations of the aminoacyl-tRNA synthetase-interacting factor 3 (AIMP3) that affect its interaction with ataxia-telangiectasia mutated (ATM) kinases and ability to activate p53 (a tumor suppressor protein) have been reported in human chronic myeloid leukemia patients (Kim et al. 2008).